Skip to main content
All lobbying filings

MEHLMAN CONSULTING, INC.

Lobbying for THE CAMPAIGN FOR SUSTAINABLE RX PRICING · A coalition of organizations working on market-based solutions to drug pricing.

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Income
$90,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 1
  • SEAN BRADY New on this filing
    Previously held: Dir Leg Affairs (DOC, Intl Trade Admin); CoS, Dep. CoS/ LD, SLA, LA, Staff Asst (Rep. Vern Buchanan); Intern (Rep. Fred Upton); Intern (Rep. Dan Lungren)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Taxation/Internal Revenue Code

S. 1785/H.R. 3010 - The No Handouts for Drug Advertisements Act.

Medicare/Medicaid

Prescription drug pricing issues. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S. 229 - The Drug-price Transparency for Consumers (DTC) Act.

Pharmacy

Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954/H.R. 5526 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 2630 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R.1262 - Mikaela Naylon Give Kids a Chance Act. S. 3014 - Ensuring Timely Access to Generics Act of 2025 S. 1414 - Expedited Access to Biosimilars Act

Copyright/Patent/Trademark

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

 Bills named in this filing 26
  • H.R. 3789
    DTC Act of 2025
  • S. 229
    DTC Act of 2025
  • H.R. 1843
    To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
  • S. 1032
    Major Richard Star Act
  • S. 1954
    Biosimilar Red Tape Elimination Act
  • H.R. 5526
    Biosimilar Red Tape Elimination Act
  • S. 1095
    Stop STALLING Act
  • S. 2630
    Saving NSF’s Workforce Act
  • H.R. 1262
    Mikaela Naylon Give Kids a Chance Act
  • S. 3014
    Ensuring Timely Access to Generics Act of 2025
  • S. 1414
    Expedited Access to Biosimilars Act
  • S. 1040
    Drug Competition Enhancement Act
  • S. 1041
    Affordable Prescriptions for Patients Act
  • S. 1096
    Preserve Access to Affordable Generics and Biosimilars Act
  • S. 1097
    Interagency Patent Coordination and Improvement Act of 2025
  • H.R. 4570
    Interagency Patent Coordination and Improvement Act of 2025
  • S. 43
    Skinny Labels, Big Savings Act
  • H.R. 6485
    Skinny Labels, Big Savings Act
  • H.R. 3269
    ETHIC Act
  • S. 2276
    ETHIC Act
  • H.R. 3160
    PREVAIL Act
  • S. 1533
    A bill to amend title 38, United States Code, to make permanent and codify the pilot program for use of contract physic…
  • H.R. 3152
    Patent Eligibility Restoration Act of 2025
  • S. 1546
    Patent Eligibility Restoration Act of 2025
Show all 26 bills
  • S. 1785
    No Handouts for Drug Advertisements Act
  • H.R. 3010
    No Handouts for Drug Advertisements Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem